CA
NZ
UK
AU
IND
US
The transaction lifted cash reserves just as the company prepares for Phase 1b topline data later in 2026, a critical milestone for its lead antiviral candidate.
Addus HomeCare delivered adjusted earnings per share of $1.73 for the quarter ended June 30, 2026, precisely in line with the consensus estimate. The match confirms the company’s ability to meet market expectations, reinforcing confidence in its earnings visibility and supporting the recent share-price …
AirSculpt Technologies Inc. (NASDAQ: AIRS) is scheduled to release its second quarter fiscal 2026 results on August 10, a key event for investors anticipating insights into the company's financial health. The earnings report follows a previous quarter where AirSculpt reported an EPS of $-0.01, …
Corvex, Inc. (NASDAQ: MOVE) disclosed a multi-year partnership to supply a prominent AI firm with NVIDIA Blackwell GPU clusters utilizing Quantum-2 InfiniBand networking, representing an expansion of an earlier agreement.
A wide-ranging set of corporate disclosures moved across the biopharma and technology landscape in a single session, spanning a patent allowance, a commercial cell-therapy ramp, a sharply cut earnings outlook, a biomarker partnership, an encouraging gene-therapy safety readout, a non-dilutive financing round, a new …
ClearPoint Neuro (NASDAQ: CLPT) released financial results for the second quarter of 2026, noting that revenue reached $10.9 million, an 18% increase compared to the previous year that nevertheless fell short of analyst estimates.
AdaptHealth Corp. (NASDAQ: AHCO) shared its second-quarter 2026 financial results, emphasizing the ongoing divestiture of its Diabetes Health segment to Cardinal Health for $235 million as part of a broader portfolio optimization strategy.
Bruker Corporation (NASDAQ: BRKR) delivered second-quarter 2026 financial results highlighting increased revenue and expanded operating margins, though these operational gains were overshadowed by a substantial non-cash goodwill impairment charge, resulting in a reported GAAP net loss for the period.
Cocrystal Pharma, Inc. (NASDAQ: COCP) shares closed up 15% at $0.94 after the company secured a $5.0 million strategic private placement from its primary institutional supporter, OPKO Health, Inc. (NASDAQ: OPK), led by Dr. Phillip Frost.
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) disclosed that SRX Global (NYSE American: SRXH) has secured an equity position in the firm, a strategic investment the company said underscores the potential value of its late-stage neuroscience development programs.
Please wait processing your request...